[Special Stock] Syntekabio Derives Remdesivir-Like Candidate Substance... Demonstrates Excellence of AI Drug Discovery Platform

[Asia Economy Reporter Hyungsoo Park] Syntekabio's stock price is on the rise. The news that one of the candidate drugs predicted to be effective against the novel coronavirus infection (COVID-19) using a drug repositioning model jointly researched with a national research institute shows excellent efficacy appears to have influenced the stock price.

At 10:33 AM on the 1st, Syntekabio was trading at 12,450 KRW, up 16.9% from the previous trading day.

Earlier, in February, Syntekabio utilized artificial intelligence based on data of proteolytic enzymes that play a key role in the gene expression and proliferation of the COVID-19 virus to discover candidate substances.

Using the data, supercomputing power, and its own AI-based novel drug discovery platform, approximately 3,000 pharmaceuticals were screened, and 30 candidate repositioning drugs were identified. Verification studies comparing efficacy with Remdesivir were conducted with a national research institute equipped with a BSL-3 facility. It was confirmed that the final one drug with excellent efficacy had COVID-19 inhibitory effects similar to those of Remdesivir.

The company judged that this substance, which has been used as a respiratory disease treatment, has meaningful clinical potential due to advantages such as ▲infection prevention effects in patients with underlying respiratory diseases ▲long-term safety data compared to Remdesivir ▲and convenience as an oral medication.

Yoon Sun-il, Director of Business Development, stated, "The total time taken to implement the drug repositioning model for COVID-19 and to verify initial experiments was six weeks," adding, "We reduced research and development time and costs at a rapid pace."

He also added, "It is meaningful that Syntekabio's AI solution was utilized and verified," and "We expect that follow-up research on respiratory disease treatments will provide differentiated solutions to patients."

This content was produced with the assistance of AI translation services.